GenMark Diagnostics' Q2 Revenues Rise 44 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Wednesday that revenues for its second quarter increased 44 percent year over year with strong growth in reagent and instrument revenues.

For the three months ended June 30, total revenues rose to $5.2 million from $3.6 million and beat the average Wall Street estimate of $5.1 million. The increase, GenMark said, "reflects an increase in the number of systems placed at customer sites, growth in test menus, and an increase in the number of tests sold."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.